Price$3.07-0.06 (-1.76%)
2026-04-212026-07-24
News · 26 weeks44-100%
2026-02-012026-07-26
Mix1090d
- Other7(70%)
- SEC Filings2(20%)
- Insider1(10%)
Latest news
25 items- PRLife Sciences Virtual Investor Forum Presentations Now Available for On-Demand ViewingNEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD
- PRLife Sciences Virtual Investor Forum Agenda Announced for June 24th & 25thNEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings
- PRNasus Pharma to Participate in the Zacks Life Sciences Investor ForumTEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management will present live at the Zacks Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, to be held virtually on June 24-25, 2026. The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. Nasus invites individual and institutional investors, as well as advisors and
- INSIDERChief Executive Officer Teleman Dan Benjamin bought $20,305 worth of Ordinary Shares (6,550 units at $3.10), increasing direct ownership by 4% to 163,541 units (SEC Form 4)4 - Nasus Pharma Ltd (0002029039) (Issuer)
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- PRNasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study in Third Quarter of 2026 TEL AVIV, Israel, June 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a preclinical pharmacokinetic ("PK") and safety study of NS003, the Company's proprietary intranasal powder formulation of ondansetron being developed for chemotherapy and post-operative nausea and vomiting. Ondanse
- PRNasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of AnaphylaxisTEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, June 10, 2026 at 8:00 AM ET featuring Michael S. Blaiss, MD (Medical College of Georgia, Good Samaritan Health Center of Gwinnett) and Joel Brooks, DO, MPH (Columbia University Vagelos College of Physicians and Surgeons, New York-Presbyterian Morgan Stanley Children's Hospital), who will join members of the Company's management to discuss the unmet need and current treatment landscape
- SECSEC Form S-8 filed by Nasus Pharma Ltd.S-8 - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.SCHEDULE 13G - Nasus Pharma Ltd (0002029039) (Subject)
- PRNasus Pharma to Participate in Upcoming Investor ConferencesTEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences. Market Movers Investor SummitMay 5, 2026, New York, NYChief Financial Officer Eyal Rubin will participate in 1x1 meetings. D. Boral Capital Global ConferenceMay 7, 2026, New York, NYChief Financial Officer Eyal Rubin will participate in 1x1 meetings. Interested investors should contact their respective representatives at the sponsoring institutions to request meetings. About Nasu
- INSIDERSEC Form 4 filed by Teleman Dan Benjamin4 - Nasus Pharma Ltd (0002029039) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Nasus Pharma Ltd.SCHEDULE 13G - Nasus Pharma Ltd (0002029039) (Subject)
- INSIDERSEC Form 4 filed by Teleman Dan Benjamin4 - Nasus Pharma Ltd (0002029039) (Issuer)
- SECSEC Form EFFECT filed by Nasus Pharma Ltd.EFFECT - Nasus Pharma Ltd (0002029039) (Filer)
- INSIDERSEC Form 3 filed by new insider Rubin Eyal3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Teleman Dan Benjamin3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Silberman David3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hershman Ronnie3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shacham Sharon3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gilboa Udi3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Megiddo Dalia3 - Nasus Pharma Ltd (0002029039) (Issuer)
- INSIDERSEC Form 3 filed by new insider Israel Isaac3 - Nasus Pharma Ltd (0002029039) (Issuer)
- SECSEC Form POS AM filed by Nasus Pharma Ltd.POS AM - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form 6-K filed by Nasus Pharma Ltd.6-K - Nasus Pharma Ltd (0002029039) (Filer)
- SECSEC Form 20-F filed by Nasus Pharma Ltd.20-F - Nasus Pharma Ltd (0002029039) (Filer)
NSRX FAQ
5 questionsWhere does NSRX stock trade?
Nasus Pharma Ltd. (NSRX) is listed on AMEX.What sector and industry is NSRX in?
Nasus Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nasus Pharma Ltd. go public?
Nasus Pharma Ltd. (NSRX) completed its IPO in 2025.What companies are similar to NSRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NSRX side-by-side with any of them on Quantisnow.How can I track NSRX on Quantisnow?
Quantisnow aggregates Nasus Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NSRX to receive live email and push alerts on every new disclosure.